Transgenic, a startup focused on genetic testing, signed a non-exclusive licnese for a recombinant model mouse for Alzheimer’s disease developed by Hiroshi MORI of Osaka City University. The model mouse carries an amyloid β precursor protein (APP) gene mutation uniquely found in patients with familial Alzheimer’s disease. In these mice, Aβ oligomers are formed, and cognitive impairment associated with aging characteristic of Alzheimer’s disease are observed. Transgenic will offer trials in the central nervous area of indications using this and related mice.

Transgenic press release, June 20, 2017